[A cooperative study of alternating immunochemotherapy with futraful and PSK (second report)--3-year survival rate].
Patients who had undergone gastrectomy for stomach cancer were placed on adjuvant chemotherapy two weeks after surgery. They were divided into three groups according to the following regimen in order to compare the 3-year survival rate : in the first group, administration of futraful was carried out for 3 consecutive months and followed by administration of PSK for 2 consecutive months. This course was repeated for more than 2 courses. Administration of futraful in the second group was repeated for 3 consecutive months with 2 months of withdrawal and repeated for more than 2 courses. The third group received surgery alone. When all the patients of each group were compared, there was no difference in 3-year survival rate, but the group receiving alternating therapy with futraful and PSK showed a significantly high survival rate for the first year only. Further, among patients having stage III carcinoma, those with n2 + n3 or poorly differentiated adenocarcinoma had a remarkably high survival rate.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000284:Administration, Oral; D004334:Drug Administration Schedule; D005472:Fluorouracil / Q000031:analogs & derivatives*; D005743:Gastrectomy; D006801:Humans; D011182:Postoperative Care; D011509:Proteoglycans / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D011509:Proteoglycans; D005641:Tegafur; C010770:polysaccharide-K; D005472:Fluorouracil